Pharmaceutical Association of Malaysia

What Pharmaceutical Association of Malaysia does

Pharmaceutical Association of Malaysia (PhAMA) is a non-governmental trade association established in 1972, representing approximately 40 member companies — predominantly the largest global biopharmaceutical multinational corporations operating in Malaysia, including Pfizer, Roche, Novartis, AstraZeneca, MSD, GSK, Johnson & Johnson, Bayer, Merck, Boehringer Ingelheim, AbbVie, Takeda, Sanofi-aligned entities, and Amgen. The organization's mandate is to drive availability and accessibility of innovative medicines in Malaysia through policy advocacy, regulatory engagement, market access work, and industry capability building. It operates through five specialized committees (Policy & IPR, Market Access & Procurement, Regulatory Affairs, Clinical Research, and Ethics & Compliance) and is governed by a Board of Directors elected every two years from ordinary member representatives, currently led by President Kam Ai Teng (2025-2027 term).

PhAMA's core deliverables are institutional rather than technology products. They include the PhAMA Code of Practice for Prescription (Ethical) Products (currently Edition 23, 2025) and a separate Code of Conduct for OTC products, which set ethical marketing standards enforced across the industry. The association publishes Industry Fact Books, White Papers (self-care, value-based medicines, innovative medicines access), and formal position statements on IP, generics, biosimilars, halal pharmaceuticals, and price control. PhAMA also convenes the Malaysia Cancer Care Coalition (M3C), established in 2017, and operates a Code of Practice Chatbot on its website for digital access to governance guidelines. It is embedded in global networks (IFPMA, GSCF, WHO, PhRMA) and domestic networks (MOH, NPRA, ICR, IMR, CRM, MPS, MMA, APHM, Academy of Medicine Malaysia).

The business model is a subscription-based membership fee structure. Ordinary members (pharmaceutical manufacturers, agents, representatives, or distributors) pay a tier-based annual subscription with a MYR 1,000 entry fee and have voting rights. Associate members (vendors, service providers, partners to the pharma industry) pay a flat MYR 15,000 annual subscription and a MYR 3,000 entry fee, without voting rights. Membership is renewed annually each January. A 5-6 person Secretariat, currently with a vacant Executive Director seat, runs operations from Petaling Jaya, Selangor. The primary GTM lever is community-led and event-driven: high-level access to government officials, daily media industry trackers, monthly distributor turnover surveys, HRDF-claimable training, and networking with public/private sector stakeholders.

Name

Pharmaceutical Association of Malaysia

Legal name

Pharmaceutical Association of Malaysia

Website

https://phama.org.my

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

1–10 employees

Short description

Pharmaceutical Association of Malaysia (PhAMA) is a 1972-established trade association representing roughly 40 innovator pharmaceutical companies — primarily global biopharma MNCs — operating in Malaysia, providing policy advocacy, regulatory engagement, and industry governance.

Ownership category

akta.pro rank

Product category

Pharmaceutical Trade Association Services

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Conformity Assessment, Testing, Inspection & Certification Cooperation (BPADANAD)

akta.pro secondary industry

KOL Engagement & Medical Education (Advisory Boards/CME Support) (HLAGALAM)

Keywords

• Pharmaceutical trade association
• Industry advocacy services
• Regulatory policy consulting
• Healthcare industry networking
• Ethical marketing governance

Headquarters

HQ city

Petaling Jaya

HQ country

Malaysia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Fees: PhAMA generates revenue through annual membership fees. Ordinary members pay based on a tier system, while associate members pay MYR 15,000 annually. Entry fees are MYR 1,000 for ordinary members and MYR 3,000 for associate members. Membership is renewable every January and valid until December.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

PhAMA is a non-governmental trade association representing 40 innovator pharmaceutical companies in Malaysia. It provides industry advocacy, policy-shaping, regulatory affairs support, market access facilitation, and HRDF-claimable technical training to its members. The association also produces governance frameworks (Code of Practice), industry publications, and manages the Malaysia Cancer Care Coalition (M3C).

Product overview

Pharmaceutical Association of Malaysia (PhAMA) is a trade organization representing 40 member companies, primarily global biopharmaceutical companies. The organization does not offer a unified software product but provides a portfolio of governance frameworks, publications, and industry initiatives. Core offerings include the PhAMA Code of Practice (currently Edition 23, 2025) governing ethical marketing of prescription products and a separate Code of Conduct for OTC products. The association produces industry publications including Fact Books, White Papers on self-care and value-based medicines, and position statements on intellectual property, generics, biosimilars, and pricing. PhAMA operates through five committees addressing Policy & IPR, Market Access, Regulatory Affairs, Clinical Research, and Ethics. The association also hosts a Code of Practice Chatbot on its website. Additionally, PhAMA manages the Malaysia Cancer Care Coalition (M3C), established in 2017 to improve cancer care outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• Malaysia Cancer Care Coalition (M3C): Coalition established in 2017 to elevate cancer care and improve patient outcomes in Malaysia, focusing on early intervention, public-private partnerships, and alignment with the National Strategic Plan for Cancer Control Programme.

Products and services

• PhAMA Code of Practice for Prescription (Ethical) Products Foundational governance document establishing ethical marketing guidelines and industry standards for prescription pharmaceutical products. Currently in Edition 23 (2025).
• PhAMA Code of Conduct - Non Prescription (OTC) Guidelines governing the marketing and promotion of over-the-counter pharmaceutical products.
• PhAMA Code of Practice Chatbot Standalone digital chatbot tool embedded on the PhAMA website, assisting users with queries about the Code of Practice guidelines.
• PhAMA Industry Fact Book 2022 Industry publication providing data and analysis on the pharmaceutical sector in Malaysia, marking 50 years of innovative medicines in Malaysia.
• PhAMA Unlocking Malaysia Potential in Clinical Trials Fact Book 2024 Perspective publication from multinational pharmaceutical companies on Malaysia's clinical trial readiness and potential.
• PhAMA Self Care White Paper: Engage and Educate White paper focused on self-care engagement and education strategies for patients and healthcare consumers.
• Malaysia Cancer Care Coalition (M3C) Coalition established in 2017 focused on elevating cancer care and improving patient outcomes through early intervention, public-private partnerships, and alignment with national cancer control strategies.
• PhAMA Ordinary Membership Annual membership tier for pharmaceutical companies engaged in manufacturing, agency, representation, or distribution in Malaysia, with voting rights for Board of Directors elections. Entry fee MYR 1,000; annual subscription tier-based.
• PhAMA Associate Membership Annual membership tier for individuals, firms, or companies not directly involved in pharmaceutical business but serving as vendors and partners. Entry fee MYR 3,000; annual subscription MYR 15,000.
• PhAMA Industry Technical Training (HRDF-claimable) Industry technical training programs (HRDF-claimable) for pharmaceutical industry employees, including workshops, Code of Practice workshops, and capability building sessions.

Quantifiable outcome

• Malaysia recognized as Top 30 globally and leader in Southeast Asia for clinical trial readiness (Rethinking Clinical Trial Country Prioritization 2024)
• +1 more outcomes

Named customers31 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

16 partnerships are on record, tiered domestic core, global flagship, global core, regional core and domestic flagship initiative.

• University Malaya Medical Centre (UMMC)domestic coreStrategic or Co-development Partner · 9 March 2026PhAMA-UMMC MoU Signing held on 9 March 2026 for collaboration in healthcare research and development.
• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)global flagshipStrategic or Co-development PartnerIFPMA represents global research-based pharmaceutical companies and associations with 2 million members. IFPMA has official relations with the United Nations. PhAMA collaborates on global pharmaceutical industry standards and advocacy.
• Global Self-Care Federation (GSCF)global flagshipStrategic or Co-development PartnerGSCF represents associations and manufacturers in self-care industry, aiming to create a healthier world through responsible self-care. Has official relations with WHO.
• World Health Organization (WHO)global coreStrategic or Co-development PartnerWHO leads global efforts to expand Universal Health Coverage, directs and coordinates world health capacities and response to health emergencies.
• Pharmaceutical Research and Manufacturers of America (PhRMA)global flagshipStrategic or Co-development PartnerPhRMA conducts effective advocacy for public policies that encourage discovery of important new medicines for patients by biopharmaceutical research companies.
• APAC (Asia Pacific CEOs)regional coreStrategic or Co-development PartnerAPAC is an industry-driven initiative led by R&D-based pharmaceutical associations from Asian economies with mission of expediting launch of innovative medicines for Asian population.
• Malaysian Pharmacists Society (MPS)domestic coreStrategic or Co-development PartnerMPS plays important role in development of pharmacy and pharmaceutical education, fostering intra-professional relationships, and improving pharmacy science for public welfare.
• Malaysian Medical Association (MMA)domestic coreStrategic or Co-development PartnerMMA is the premier organization for medical profession in Malaysia, voicing concerns of doctors and protecting rights of both doctors and patients.
• Association of Private Hospitals of Malaysia (APHM)domestic coreStrategic or Co-development PartnerAPHM represents private hospitals and medical centers in Malaysia, with over 100 members throughout Malaysia. Key partners with public sector in comprehensive medical care.
• Academy of Medicine Malaysiadomestic coreStrategic or Co-development PartnerEstablished 1974, the Academy brings together various medical specialties to enable them to speak with one voice. Currently has 11 Colleges under its umbrella.
• Ministry of Health Malaysiadomestic coreStrategic or Co-development PartnerMOH ensures Malaysians achieve and sustain a certain level of health to lead a productive lifestyle. PhAMA provides professional and technical advice to MOH on pharmaceutical matters.
• National Pharmaceutical Regulatory Agency (NPRA)domestic coreStrategic or Co-development PartnerNPRA safeguards quality, efficacy, and safety of pharmaceuticals through registration, licensing and monitoring. Serves as WHO Collaborating Centre for Regulatory Control of Pharmaceuticals.
• Institute for Clinical Research (ICR)domestic coreStrategic or Co-development PartnerICR coordinates Investigator-Initiated and Industry-Sponsored Clinical Trials and promotes Malaysia as centre of excellence for clinical trials in the region.
• Institute for Medical Research (IMR)domestic coreStrategic or Co-development PartnerIMR promotes moral and material well-being of Malaysians and explores tropical medicine. Seeks to become world-renowned for biomedical research.
• Malaysia Cancer Care Coalition (M3C)domestic flagship initiativeStrategic or Co-development PartnerM3C was established in 2017 to Elevate Cancer Care and Improve Patient Outcomes. Focuses on early intervention, public-private partnerships for innovative financing, and alignment with National Strategic Plan for Cancer Control Programme.
• Clinical Research Malaysia (CRM)domestic coreStrategic or Co-development PartnerPhAMA played key role in formation of CRM which coordinates clinical research activities in Malaysia.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• European Federation of Pharmaceutical Industries and Associations (EFPIA): Regional trade association representing the pharmaceutical industry in Europe. Highly comparable in structure and mission to PhAMA: industry representation, policy advocacy, ethical marketing codes, and engagement with regulators and health authorities.
• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Global federation of research-based pharmaceutical companies and associations. PhAMA explicitly cites IFPMA as a partner; both serve as industry advocacy bodies for innovator pharma, with IFPMA operating at the global tier and PhAMA at the national tier.
• Japan Pharmaceutical Manufacturers Association (JPMA): Japan's pharmaceutical industry association, comprising mainly research-oriented manufacturers. Operates a similar advocacy, code-of-conduct, and policy-shaping model to PhAMA's, with comparable committee-based governance.
• Pharmaceutical Research and Manufacturers of America (PhRMA): US-based advocacy organization for biopharmaceutical research companies. Listed as a direct PhAMA partner; both organizations share a mandate to advocate for public policies that support innovative medicine discovery and patient access.

Regional players

• Thai Pharmaceutical Manufacturers Association (TPMA): Thailand's pharmaceutical manufacturers' association, advocating for both local and multinational pharmaceutical companies. Directly comparable in ASEAN-regional context to PhAMA's mandate in Malaysia.
• Korea Pharmaceutical Manufacturers Association (KPMA): National pharmaceutical industry association in South Korea. Closest regional analogue to PhAMA in structure: member-driven advocacy body engaging with government on regulation, pricing, and market access for the innovator pharma industry.
• Gabungan Perusahaan Farmasi Indonesia (GP Farmasi / IPMG): International Pharmaceutical Manufacturers Group in Indonesia representing research-based pharmaceutical companies. A direct ASEAN peer to PhAMA with a similar multinational-member-driven advocacy model.
• Singapore Association of Pharmaceutical Industries (SAPI): Pharmaceutical industry association in Singapore, often co-listed with PhAMA in regional industry forums. Highly comparable in size, scope, and mission: representing innovator pharma companies in a single ASEAN market.
• Indian Pharmaceutical Alliance (IPA): India's leading pharmaceutical industry alliance of research-based national and multinational companies. Comparable trade association structure: policy advocacy, code of practice, and engagement with regulators.

Others

• Malaysian Pharmaceutical Society (MPS): Domestic Malaysian partner organization of PhAMA, focused on pharmacists rather than pharma companies. Adjacent peer — both operate in Malaysian pharmaceutical policy circles and have formal partnership ties, though MPS represents individual pharmacy professionals rather than manufacturers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PhAMAOfficial
• YouTubeyoutube.com/@pharmaceuticalassociationo5885
• Facebookfacebook.com/PhAMAofficial
• LinkedInlinkedin.com/company/pharmaceutical-association-of-malaysia

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaceutical Association of Malaysia